我的账户 7×24小时客服热线:400-829-7929 语言:
热门产品: 人参皂苷Rh2,人参皂苷Rg3,胡萝卜苷, 木犀草苷
产品分类
在线咨询
联系电话:
销售:
400-829-7929(7*24小时)
028-82633860
028-82633397 
028-
82633165
技术服务和产品定制:
028-82633987
在线服务:  
沈帅 
文静  点击这里给我发消息
贺丹丹  
点击这里给我发消息
      
文献信息

Therapeutic effect and molecular mechanism of the ultra-low molecule compound K on multiple myeloma

期刊名:Biomedicine & Pharmacotherapy
文献编号:
文献地址: https://www.sciencedirect.com/science/article/pii/S075333222401326X
发表日期:November 2024
Multiple myeloma (MM) is an incurable hematologic cancer that originates from plasma cells and occurs primarily in patients over 60. The prognosis of MM has improved after the introduction of new treatments, such as thalidomide, bortezomib, and lenalidomide. However, in recurrent and refractory MM patients, factors such as age and drug toxicity are important when choosing treatment options. Because of this, the demand for novel, low-toxicity drugs is increasing. This study demonstrated that KBB-N1, an ultra-low molecular weight ginsenoside compound K, effectively treated MM by increasing the expression of phosphorylated p53. Given its minimal toxicity to hematopoietic stem cells and major organs, KBB-N1 is a promising new drug for treating MM in older patients.
相关产品